Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022;27(4):330-339.
doi: 10.5863/1551-6776-27.4.330. Epub 2022 May 9.

A Multicenter Analysis of Changes in Pediatric Antibiotic Susceptibilities Among Staphylococcus aureus and Pseudomonas aeruginosa Isolates: 2014-2018

Jeremy S Stultz  1   2 , Emily Benefield  3 , Kelley R Lee  1   2 , Ferras Bashqoy  4 , Amy L Pakyz  5
Affiliations

A Multicenter Analysis of Changes in Pediatric Antibiotic Susceptibilities Among Staphylococcus aureus and Pseudomonas aeruginosa Isolates: 2014-2018

Jeremy S Stultz et al. J Pediatr Pharmacol Ther. 2022.

Abstract

Objective: To describe antibiotic susceptibilities for Staphylococcus aureus and Pseudomonas aeruginosa among pediatric institutions in 2018. To assess correlations between antibiotic utilization and susceptibilities.

Methods: Institutional antibiograms from 2018 were compiled among 13 institutions via a survey. Resistant pathogens and antibiotic days of therapy/1000 patient days (PD) were collected from 6 institutions over 5 years. Correlations were assessed as pooled data among all institutions and relative changes within individual institutions.

Results: All 8552 S aureus isolates in 2018 were vancomycin susceptible and 40.1% were methicillin resistant (MRSA). Among MRSA, 96.3% and 78.8% were susceptible to trimethoprim/sulfamethoxazole and clindamycin, respectively. Pooled yearly MRSA/1000 PD decreased from 2014-2018 and correlated with pooled yearly decreases in vancomycin utilization (R = 0.983, p = 0.003). Institutional relative decreases in vancomycin utilization from 2014-2018 did not correlate with institutional relative decreases in MRSA susceptibility (R = -0.659, p = 0.16). Susceptibility to meropenem was 90.9% among 2315 P aeruginosa isolates in 2018. Antipseudomonal beta-lactam susceptibility ranged from 89.4% to 92.3%. Pooled yearly meropenem-resistant P aeruginosa/1000 PD and meropenem utilization did not significantly decrease over time or correlate (both p > 0.6). Institutional relative change in meropenem utilization from 2013-2017 correlated with the institutional relative change in P aeruginosa susceptibility to meropenem from 2014-2018 (Rs = -0.89, p = 0.019).

Conclusions: Among included institutions, the burden of MRSA decreased over time. Institutional MRSA prevalence did not consistently correlate with institutional vancomycin utilization. Institutional changes in meropenem utilization correlated with P aeruginosa susceptibility the following year. Pooled analyses did not illustrate this correlation, likely owing to variability in utilization between institutions.

Keywords: Pseudomonas aeruginosa; Staphylococcus aureus; antibiotic resistance; antimicrobial stewardship; meropenem; pediatrics; vancomycin.

PubMed Disclaimer

Conflict of interest statement

Disclosures. Three authors (JSS, EB, FB) are members of the PPA PBRN. Otherwise, the authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts, and honoraria. JSS and KRL had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Figures

Figure 1.
Figure 1.
Pooled MRSA percentage and vancomycin utilization over time (A) and pooled MRSA burden versus time (B) among 6 pediatric institutions.
Figure 2.
Figure 2.
Pooled yearly MRSA burden versus vancomycin utilization (A) and institutional relative changes from 2014 to 2018 in MRSA proportion versus vancomycin utilization (B) among 6 pediatric institutions.
Figure 3.
Figure 3.
Pooled PSA susceptibility and meropenem utilization over time (A*,†) and pooled meropenem resistant PSA burden versus time (B) among 6 pediatric institutions.
Figure 4.
Figure 4.
Pooled meropenem resistant PSA burden versus prior year meropenem utilization (A) and institutional relative changes from 2014 to 2018 in meropenem susceptibility versus meropenem utilization from 2013–2017 (B) among 6 pediatric institutions.
See this image and copyright information in PMC

References

    1. Griffith HG, Dantuluri K, Thurm C et al. Considerable variability in antibiotic use among US children's hospitals in 2017–2018. Infect Control Hosp Epidemiol . 2020;41(5):571–578. - PMC - PubMed
    1. Gerber JS, Newland JG, Coffin SE et al. Variability in antibiotic use at children's hospitals. Pediatrics . 2010;126(6):1067–1073. - PMC - PubMed
    1. Lake JG, Weiner LM, Milstone AM et al. Pathogen distribution and antimicrobial resistance among pediatric healthcare-associated infections reported to the National Healthcare Safety Network, 2011–2014. Infect Control Hosp Epidemiol . 2018;39(1):1–11. - PMC - PubMed
    1. Larru B, Gong W, Vendetti N et al. Bloodstream infections in hospitalized children: epidemiology and antimicrobial susceptibilities. Pediatr Infect Dis J . 2016;35(5):507–510. - PubMed
    1. Hamdy RF, Dona D, Jacobs MB, Gerber JS. Risk factors for complications in children with Staphylococcus aureus bacteremia. J Pediatr . 2019;208:214–220.e2. - PubMed

LinkOut - more resources